Lung Cancer Clinical Trial

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

Summary

The purpose of this study is to determine if liquid biopsies will reduce time to begin treatment in participants with non-small cell lung cancer (NSCLC). A liquid biopsy is a test done on a sample of blood to look for cancer cells.

View Full Description

Full Description

Referred patients with newly diagnosed NSCLC who have not had genetic testing for targetable mutations will be considered for this study. The primary objective of this prospective study is to examine if using liquid biopsy can reduce time to treatment (TTT) in external participants with NSCLC. Secondary objectives examined will include time to actionable genetic testing results (ctDNA or tissue), rate of actionable biomarker discovery, and rate of appropriate guideline-directed therapy based upon testing results.

A liquid biopsy is a test done on a sample of blood to look for cancer cells. A traditional biopsy, which requires tissue to be removed from the body, takes 14 days to be tested. A liquid biopsy takes 7 days which significantly shortens the TTT for those diagnosed with NSCLC. By studying this, doctors may be better able to determine if this will be beneficial and result in less time taken to treat cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants with newly diagnosed, advanced nonsquamous NSCLC referred to the Cleveland Clinic Taussig Cancer Center from outside centers without prior testing results available for targetable genetic alterations
Plan to receive systemic therapy at the Cleveland Clinic, OR plan to receive systemic therapy at an outside site while maintaining either intermittent follow up at Cleveland Clinic or with electronic health record access through Care Everywhere.

Exclusion Criteria:

Prior therapy for this diagnosis of NSCLC
Prior adequate molecular testing done for the current diagnosis of NSCLC

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT04474613

Recruitment Status:

Recruiting

Sponsor:

Case Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland Ohio, 44915, United States More Info
Nathan Pennell, MD, PhD
Contact
866-223-8100
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT04474613

Recruitment Status:

Recruiting

Sponsor:


Case Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider